• Risk of CNS recurrence associated with skeletal involvement is a
matter of debate, with rates of 4% and 0.6% respectively for
DLCL patients with and without skeletal involvement
• In the IELSG-14 study, CNS involvement occurred in 2.5% of
patients with primary bone DLCL
• Available evidence suggests that CNS prophylaxis is superfluous
in primary bone DLCL
Therapeutic issues